The UPMC Hillman Cancer Center, previously titled the University of Pittsburgh Cancer Institute, is a National Cancer Institute-designated Comprehensive Cancer Center located in the Hillman Cancer Center in the Shadyside neighborhood of Pittsburgh, Pennsylvania, United States, adjacent to UPMC Shadyside.

During the past decade, UPMC Hillman Cancer Center Investigational Drug Service conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "UPMC Hillman Cancer Center Investigational Drug Service" #1 collaborator was "Eli Lilly and Company" with 1 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator and "Ono Pharmaceutical Co. Ltd" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "UPMC Hillman Cancer Center Investigational Drug Service" are "Advanced Solid Tumor" (1 trials), "Homologous Recombination Deficient-Positive Malignancies Agnostic" (1 trials), "Metastatic Solid Tumor" (1 trials), "Neoplasms" (1 trials) and "Poorly Differentiated Neuroendocrine Carcinomas" (1 trials). Many other conditions were trialed in "UPMC Hillman Cancer Center Investigational Drug Service" in a lesser frequency.

Most popular intervention types in "UPMC Hillman Cancer Center Investigational Drug Service" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "5-FU" (1 trials), "Bevacizumab" (1 trials), "Capecitabine" (1 trials), "Cetuximab" (1 trials) and "Encorafenib" (1 trials). Other intervention names were less common.

The vast majority of trials in "UPMC Hillman Cancer Center Investigational Drug Service" are 2 trials for "All" genders.

Currently, there are NaN active trials in "UPMC Hillman Cancer Center Investigational Drug Service". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in UPMC Hillman Cancer Center Investigational Drug Service, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in UPMC Hillman Cancer Center Investigational Drug Service, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".